| Literature DB >> 16331792 |
Barry Bresnihan1, Dominique Baeten, Gary S Firestein, Oliver M Fitzgerald, Danielle M Gerlag, Jasper J Haringman, Iain B McInnes, Richard J Reece, Malcolm D Smith, Ann-Kristin Ulfgren, Douglas J Veale, Paul Peter Tak.
Abstract
Synovial tissue analysis has considerable potential for future randomized controlled trials (RCT). The synovial membrane is the target tissue in treatment strategies of rheumatoid arthritis and other arthropathies. Effective modulation of synovitis is critical when attempting to control symptoms and signs, to prevent joint damage, and to maintain function. In RCT, the systematic evaluation of changes in synovial tissue after commencing treatment enables identification of an early therapeutic effect, using relatively small numbers of patients. This special interest group is working on establishing the evidence to have this endpoint meet the OMERACT filter criteria.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16331792
Source DB: PubMed Journal: J Rheumatol ISSN： 0315-162X Impact factor: 4.666